Catumaxomab (Removab®)

Assessment Status Rapid Review complete
Drug Catumazomab
Brand Removab®
Indication For the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.
Assessment Process
Rapid review commissioned 05/08/2011
Rapid review completed 06/09/2011
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.